DIQTA 1.0: Drug-Induced QT Prolongation Atlas

GALANTAMINE HYDROBROMIDE

Classification:Most-DIQT concern

Severity Score:4.0

OVERDOSAGE
In one postmarketing report, one patient who had been taking 4 mg of galantamine daily for a week inadvertently ingested eight 4 mg tablets (32 mg total) on a single day. Subsequently, she developed bradycardia, QT prolongation, ventricular tachycardia and torsades de pointes accompanied by a brief loss of consciousness for which she required hospital treatment. Two additional cases of accidental ingestion of 32 mg (nausea, vomiting, and dry mouth; nausea, vomiting, and substernal chest pain) and one of 40 mg (vomiting), resulted in brief hospitalizations for observation with full recovery. One patient, who was prescribed 24 mg/day and had a history of hallucinations over the previous two years, mistakenly received 24 mg twice daily for 34 days and developed hallucinations requiring hospitalization. Another patient, who was prescribed 16 mg/day of oral solution, inadvertently ingested 160 mg (40 mL) and experienced sweating, vomiting, bradycardia, and near-syncope one hour later, which necessitated hospital treatment. His symptoms resolved within 24 hours.

Current Drug

Other Drugs

QT Prolongation

24078

Other ADRs

3281

38378306

Odds Ratio = 6.802

ATC Code(s):

Active Ingredient:galantamine hydrobromide

Active Ingredient UNII:MJ4PTD2VVW

Drugbank ID:DB00674

PubChem Compound:9651

CTD ID:D005702

PharmGKB:PA449726

CAS Number:357-70-0

Dosage Form(s):capsule, extended release; tablet, film coated

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3

N/A